Filtered By:
Cancer: Leukemia
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 28070 results found since Jan 2013.
My current protocol
I have been getting quite a number of requests from blog readers wanting to know more or less the same things: how much curcumin I take, how I take it (with a fat, with cocoa, etc.)…and so on and so forth…
Instead of replying to each and every one of you, which would take heaps of time, I decided to write a quick post today about this issue.
Dosage: Every day I take 8 grams of C3 Complex curcumin = the curcumin that has been used in the MM, SMM, and MGUS clinical trials.
As for brands, I prefer Doctor’s Best, simply because of its easy-to-take one-gram tablets, which you can sometimes find at a relativel...
Source: Margaret's Corner - June 29, 2017 Category: Cancer & Oncology Authors: Margaret Tags: Blogroll curcumin protocol Source Type: blogs
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
CONCLUSIONS: The risk of secondary acute myeloid leukaemia and myelodysplastic syndrome (AML/MDS) is increased but efficacy is improved among patients treated with intensified chemotherapy protocols. Treatment decisions must be tailored for individual patients. Consolidating radiotherapy is associated with an increased rate of secondary malignancies; therefore it appears important to define which patients can safely be treated without radiotherapy after chemotherapy, both for early and advanced stages. For early stages, treatment optimisation methods such as use of fewer chemotherapy cycles and reduced field or reduced-dos...
Source: Cochrane Database of Systematic Reviews - September 13, 2017 Category: General Medicine Authors: Franklin J, Eichenauer DA, Becker I, Monsef I, Engert A Tags: Cochrane Database Syst Rev Source Type: research
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
CONCLUSIONS: No trial evaluated one TPO mimetic versus another.Six trials including adult patients analysed one TPO mimetic versus placebo, sometimes combined with standard therapy in both arms. Given the uncertainty of the quality of evidence, meta-analyses show that there is little or no evidence for a difference in mortality during study and premature progress to AML. However, these assumptions have to be further explored. Treatment with TPO mimetics resulted in a lower number of MDS patients suffering from bleeding events.There is no evidence for a difference between study groups regarding transfusion requirement. Enla...
Source: Cochrane Database of Systematic Reviews - September 30, 2017 Category: General Medicine Authors: Dodillet H, Kreuzer KA, Monsef I, Skoetz N Tags: Cochrane Database Syst Rev Source Type: research
Recurrent Malignancy-Associated Atypical Neutrophilic Dermatosis With Noninfectious Shock.
We present a fatal case of a patient with chronic eosinophilic leukemia with recurrent episodes of malignancy-associated atypical neutrophilic dermatosis characterized by necrotic skin lesions, pulmonary infiltrates and noninfectious shock and we also summarize the clinical presentations of an additional 10 patients reported in the literature. We conducted a PubMed search of articles published up to and in 2015, focusing on the English and Spanish literature with SS cross-referenced with the following search terms: neutrophilic dermatosis, pyoderma gangrenosum, shock, multiorgan failure and systemic inflammatory response s...
Source: The American Journal of the Medical Sciences - December 1, 2017 Category: General Medicine Authors: Kinser KN, Panach K, Dominguez AR Tags: Am J Med Sci Source Type: research
Hey Watson, Can I Sue You?
By JAYSON CHUNG & AMANDA ZINK
Currently, three South Korean medical institutions – Gachon University Gil Medical Center, Pusan National University Hospital and Konyang University Hospital – have implemented IBM’s Watson for Oncology artificial intelligence (AI) system. As IBM touts the Watson for Oncology AI’s to “[i]dentify, evaluate and compare treatment options” by understanding the longitudinal medical record and applying its training to each unique patient, questions regarding the status and liability of these AI machines have arisen.
Given its ability to interpret data and present treatment op...
Source: The Health Care Blog - December 10, 2017 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized Source Type: blogs
Antibacterial prophylaxis in pediatric patients with leukemia.
Conclusion Antibacterial prophylaxis mainly with coverage against Gram-positive bacteria is recommended in pediatric patients with AML. For ALL patients, prophylaxis may be considered for patients who are undergoing intensive chemotherapy phases and are at high risk for infections with ciprofloxacin being the most commonly used agent. In general more studies are needed to determine the role of antibacterial prophylaxis in pediatric patients with leukemia.
Source: Saudi Pharmaceutical Journal - April 4, 2018 Category: Drugs & Pharmacology Source Type: research
Antibacterial prophylaxis in pediatric patients with leukemia
Conclusion Antibacterial prophylaxis mainly with coverage against Gram-positive bacteria is recommended in pediatric patients with AML. For ALL patients, prophylaxis may be considered for patients who are undergoing intensive chemotherapy phases and are at high risk for infections with ciprofloxacin being the most commonly used agent. In general more studies are needed to determine the role of antibacterial prophylaxis in pediatric patients with leukemia.
Source: Saudi Pharmaceutical Journal - April 7, 2018 Category: Drugs & Pharmacology Source Type: research
The effect of paternal factors on perinatal and paediatric outcomes: a systematic review and meta-analysis
AbstractBACKGROUNDMaternal factors, including increasing childbearing age and various life-style factors, are associated with poorer short- and long-term outcomes for children, whereas knowledge of paternal parameters is limited. Recently, increasing paternal age has been associated with adverse obstetric outcomes, birth defects, autism spectrum disorders and schizophrenia in children.OBJECTIVE AND RATIONALEThe aim of this systematic review is to describe the influence of paternal factors on adverse short- and long-term child outcomes.SEARCH METHODSPubMed, Embase and Cochrane databases up to January 2017 were searched. Pat...
Source: Human Reproduction Update - February 15, 2018 Category: OBGYN Source Type: research
Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
Authors: Rodgers TD, Reagan PM
Abstract
INTRODUCTION: The B-cell receptor (BCR) pathway is a crucial aspect of mature lymphocytes and is maintained in B-cell neoplasms. Many small module inhibitors targeting kinases within the BCR pathway are approved, with others in development, offering alternative treatment options to standard chemoimmunotherapy. Areas Covered: This review covers both approved inhibitors and investigational inhibitors of spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), and phosphoinositide-3-kinase (PI3K) in the treatment of B-cell lymphomas. To collect relevant articles, a literatu...
Source: Expert Opinion on Emerging Drugs - May 25, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research
Antibacterial prophylaxis in pediatric patients with leukemia
ConclusionAntibacterial prophylaxis mainly with coverage against Gram-positive bacteria is recommended in pediatric patients with AML. For ALL patients, prophylaxis may be considered for patients who are undergoing intensive chemotherapy phases and are at high risk for infections with ciprofloxacin being the most commonly used agent. In general more studies are needed to determine the role of antibacterial prophylaxis in pediatric patients with leukemia.
Source: Saudi Pharmaceutical Journal - July 5, 2018 Category: Drugs & Pharmacology Source Type: research
Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)).
CONCLUSIONS: We found no evidence for a difference between participants receiving ATRA in addition to chemotherapy or chemotherapy only for the outcome OS. Regarding DFS, CRR and on-study mortality, there is probably no evidence for a difference between treatment groups. Currently, it seems the risk of adverse events are comparable to chemotherapy only.As quality of life has not been evaluated in any of the included trials, further research is needed to clarify the effect of ATRA on quality of life.
PMID: 30080246 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - August 6, 2018 Category: General Medicine Authors: Küley-Bagheri Y, Kreuzer KA, Monsef I, Lübbert M, Skoetz N Tags: Cochrane Database Syst Rev Source Type: research
Systematic review of pre-clinical chronic myeloid leukaemia.
CONCLUSION: This is the first systematic review on pre-clinical CML. This entity requires additional large-scale studies.
PMID: 30218276 [PubMed - as supplied by publisher]
Source: International Journal of Hematology - September 14, 2018 Category: Hematology Authors: Kuan JW, Su AT, Leong CF, Osato M, Sashida G Tags: Int J Hematol Source Type: research
A Systematic Review and Meta-analysis of Subsequent Malignant Neoplasm Risk after Radioactive Iodine Treatment of Thyroid Cancer.
CONCLUSIONS: The body of evidence on whether I-131 treatment of thyroid cancer is associated with the primary outcome of any SMN is highly heterogeneous and complex. More research is needed examining the long-term risk of specific SMNs after I-131 treatment.
PMID: 30370820 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - October 30, 2018 Category: Endocrinology Tags: Thyroid Source Type: research
Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor (ClinTrialGov 00342316)
Conclusions. Applying an intention-to-treat analysis we did not demonstrate clinical benefit of sibling donor search and stem cell transplantation after a reduced intensity busulfan/fludarabine based regimen in AML patients ≥50 years in CR1. Early relapse was the main reason for preventing transplants in patients with an identified donor.Support from study groups: Canadian BMT Group, Australasian Leukaemia and Lymphoma Group, Norwegian/Swedish BMT Group, Swedish AML groupDisclosuresKiss: Alexion: Membership on an entity's Board of Directors or advisory committees, Research Funding; Otsuka: Membership on an entity's Boar...
Source: Blood - November 21, 2018 Category: Hematology Authors: Brune, M., Kiss, T. L., Wallhult, E., Anderson, H., Delage, R., Finke, J., Hebert, J., Hoglund, M., Kaare, A., Lazarevic, V., Nicklasson, M., Remes, K., Ritchie, D., Sabloff, M., Spearing, R., Spyridonidis, A., Szer, J., Ljungman, P. Tags: 732. Clinical Allogeneic Transplantation: Results: To Transplant or Not to Transplant? That Is the Question Source Type: research
